Terms: = Bone cancer AND TNFRSF17, BCMA, 608, ENSG00000048462, CD269, Q02223, BCM AND Treatment
73 results:
1. Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.
Rujirachaivej P; Siriboonpiputtana T; Luangwattananun P; Yuti P; Wutti-In Y; Choomee K; Sujjitjoon J; Chareonsirisuthigul T; Rerkamnuaychoke B; Junking M; Yenchitsomanus PT
Clin Exp Med; 2024 Apr; 24(1):90. PubMed ID: 38683232
[TBL] [Abstract] [Full Text] [Related]
2. Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and bcma-targeted Therapies.
Keller AL; Reiman LT; Perez de Acha O; Parzych SE; Forsberg PA; Kim PS; Bisht K; Wang H; van de Velde H; Sherbenou DW
Cancer Res Commun; 2024 Mar; 4(3):757-764. PubMed ID: 38421887
[TBL] [Abstract] [Full Text] [Related]
3. CD8 effector T cells enhance teclistamab response in bcma-exposed and -naïve multiple myeloma.
Firestone RS; McAvoy D; Shekarkhand T; Serrano E; Hamadeh I; Wang A; Zhu M; Qin WG; Patel D; Tan CR; Hultcrantz M; Mailankody S; Hassoun H; Shah US; Korde N; Maclachlan KH; Landau HJ; Scordo M; Shah GL; Lahoud OB; Giralt S; Murata K; Hosszu KK; Chung DJ; Lesokhin AM; Usmani SZ
Blood Adv; 2024 Apr; 8(7):1600-1611. PubMed ID: 37878808
[TBL] [Abstract] [Full Text] [Related]
4. Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy.
Casey M; Lee C; Kwok WY; Law SC; Corvino D; Gandhi MK; Harrison SJ; Nakamura K
Haematologica; 2024 Mar; 109(3):787-798. PubMed ID: 37767564
[TBL] [Abstract] [Full Text] [Related]
5. IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma.
Pisano MD; Sun F; Cheng Y; Parashar D; Zhou V; Jing X; Sompallae R; Abrudan J; Zimmermann MT; Mathison A; Janz S; Pufall MA
Haematologica; 2023 Dec; 108(12):3372-3383. PubMed ID: 37439384
[TBL] [Abstract] [Full Text] [Related]
6. Elranatamab: a new promising BispAb in multiple myeloma treatment.
Grosicki S; Bednarczyk M; Kociszewska K
Expert Rev Anticancer Ther; 2023; 23(8):775-782. PubMed ID: 37434334
[TBL] [Abstract] [Full Text] [Related]
7. γ-Secretase inhibitor in combination with bcma chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Cowan AJ; Pont MJ; Sather BD; Turtle CJ; Till BG; Libby EN; Coffey DG; Tuazon SA; Wood B; Gooley T; Wu VQ; Voutsinas J; Song X; Shadman M; Gauthier J; Chapuis AG; Milano F; Maloney DG; Riddell SR; Green DJ
Lancet Oncol; 2023 Jul; 24(7):811-822. PubMed ID: 37414012
[TBL] [Abstract] [Full Text] [Related]
8. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Newhouse R; Nelissen E; El-Shakankery KH; Rogozińska E; Bain E; Veiga S; Morrison J
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD006910. PubMed ID: 37407274
[TBL] [Abstract] [Full Text] [Related]
9. Novel models by machine learning to predict prognosis of breast cancer brain metastases.
Li C; Liu M; Zhang Y; Wang Y; Li J; Sun S; Liu X; Wu H; Feng C; Yao P; Jia Y; Zhang Y; Wei X; Wu F; Du C; Zhao X; Zhang S; Qu J
J Transl Med; 2023 Jun; 21(1):404. PubMed ID: 37344847
[TBL] [Abstract] [Full Text] [Related]
10. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract] [Full Text] [Related]
11. Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Zafar A; Huang CY; Lo M; Arora S; Chung A; Wong SW; Wolf J; Martin TG; Shah N; Banerjee R
Transplant Cell Ther; 2023 Aug; 29(8):504.e1-504.e7. PubMed ID: 37244643
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After bcma Directed CAR T-cell Therapy.
Davis JA; Sborov DW; Wesson W; Julian K; Abdallah AO; McGuirk JP; Ahmed N; Hashmi H
Transplant Cell Ther; 2023 Sep; 29(9):567-571. PubMed ID: 37225044
[TBL] [Abstract] [Full Text] [Related]
13. Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non-small cell lung cancer patients.
Tan X; Wang S; Xia H; Chen H; Xu J; Meng D; Wang Z; Li Y; Yang L; Jin Y
Invest New Drugs; 2023 Jun; 41(3):463-472. PubMed ID: 37140694
[TBL] [Abstract] [Full Text] [Related]
14. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.
Friedrich MJ; Neri P; Kehl N; Michel J; Steiger S; Kilian M; Leblay N; Maity R; Sankowski R; Lee H; Barakat E; Ahn S; Weinhold N; Rippe K; Bunse L; Platten M; Goldschmidt H; Müller-Tidow C; Raab MS; Bahlis NJ
Cancer Cell; 2023 Apr; 41(4):711-725.e6. PubMed ID: 36898378
[TBL] [Abstract] [Full Text] [Related]
15. Allogeneic Anti-bcma CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors.
Metelo AM; Jozwik A; Luong LA; Dominey-Foy D; Graham C; Attwood C; Inam S; Dunlop A; Sanchez K; Cuthill K; Rice C; Streetly M; Bentley T; Boldajipour B; Sommer C; Sasu B; Benjamin R
Cancer Res Commun; 2022 Mar; 2(3):158-171. PubMed ID: 36874402
[TBL] [Abstract] [Full Text] [Related]
16. Trends in Survival and Surgical Methods in Patients Surgically Treated for Metastatic Spinal Tumors: 25-Year Experience in a Single Institution.
Park SJ; Park JS; Lee CS; Kang BJ; Jung CW
Clin Orthop Surg; 2023 Feb; 15(1):109-117. PubMed ID: 36778984
[TBL] [Abstract] [Full Text] [Related]
17. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours.
Flugel CL; Majzner RG; Krenciute G; Dotti G; Riddell SR; Wagner DL; Abou-El-Enein M
Nat Rev Clin Oncol; 2023 Jan; 20(1):49-62. PubMed ID: 36418477
[TBL] [Abstract] [Full Text] [Related]
18. VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience.
Ghandili S; Alihodzic D; Wiessner C; Bokemeyer C; Weisel K; Leypoldt LB
Ann Hematol; 2023 Jan; 102(1):117-124. PubMed ID: 36383242
[TBL] [Abstract] [Full Text] [Related]
19. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after bcma-directed CAR T therapy.
Van Oekelen O; Nath K; Mouhieddine TH; Farzana T; Aleman A; Melnekoff DT; Ghodke-Puranik Y; Shah GL; Lesokhin A; Giralt S; Thibaud S; Rossi A; Rodriguez C; Sanchez L; Richter J; Richard S; Cho HJ; Chari A; Usmani SZ; Jagannath S; Shah UA; Mailankody S; Parekh S
Blood; 2023 Feb; 141(7):756-765. PubMed ID: 36327160
[TBL] [Abstract] [Full Text] [Related]
20. Development and manufacture of novel locally produced anti-bcma CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial.
Asherie N; Kfir-Erenfeld S; Avni B; Assayag M; Dubnikov T; Zalcman N; Lebel E; Zimran E; Shaulov A; Pick M; Cohen Y; Avivi I; Cohen C; Gatt ME; Grisariu S; Stepensky P
Haematologica; 2023 Jul; 108(7):1827-1839. PubMed ID: 36200421
[TBL] [Abstract] [Full Text] [Related]
[Next]
